Implications of Serum Paraoxonase Activity in Obesity, Diabetes Mellitus, and Dyslipidemia

Overview

Journal Indian J Endocrinol Metab

Specialty Endocrinology

Date 2013 Jul 23

PMID 23869295

Citations 27

Authors

Sunil K Kota

Lalit K Meher

Siva K Kota

Sruti Jammula

S V S Krishna

Kirtikumar D Modi

Affiliations

Soon will be listed here.

Abstract

Human serum paraoxonase 1 (PON1) is an enzyme with esterase activity, and is physically bound to high-density lipoproteins (HDL). It plays a key role in the action of HDL toward protection of lipoprotein and biological membrane against oxidative damage. It may have a protective role against atherosclerosis by virtue of its action on hydrolyzing lipid peroxides and preventing accumulation of phospholipids in oxidized low-density lipoprotein (LDL). PON1 is hypothesized to be an indicator of the risk of atherosclerosis and coronary artery disease development. Numerous studies have implicated PON1 activity in relation to various endocrine disorders. The current article reviews the clinical perspectives of PON1 activity with regards to obesity, diabetes mellitus with its complications, and dyslipidemia.

Citing Articles

Is oxidative stress - antioxidants imbalance the physiopathogenic core in pediatric obesity?.

Lupu A, Fotea S, Jechel E, Starcea I, Ioniuc I, Knieling A Front Immunol. 2024; 15:1394869.

PMID: 39176098 PMC: 11338799. DOI: 10.3389/fimmu.2024.1394869.

The Role of Polyphenols in Modulating PON1 Activity Regarding Endothelial Dysfunction and Atherosclerosis.

Sirca T, Muresan M, Pallag A, Marian E, Jurca T, Vicas L Int J Mol Sci. 2024; 25(5).

PMID: 38474211 PMC: 10931629. DOI: 10.3390/ijms25052962.

Serum Ferritin in Obese Dogs: Changes and Comparison with Other Analytes.

Franco-Martinez L, Pardo-Marin L, Sanchez-Mateos L, Munoz-Prieto A, Garcia-Martinez J, Ceron J Vet Sci. 2023; 10(7).

PMID: 37505862 PMC: 10383353. DOI: 10.3390/vetsci10070457.

Comparison of Plasma Exosome Proteomes Between Obese and Non-Obese Patients with Type 2 Diabetes Mellitus.

Wang Y, Wu Y, Yang S, Chen Y Diabetes Metab Syndr Obes. 2023; 16:629-642.

PMID: 36915396 PMC: 10008006. DOI: 10.2147/DMSO.S396239.

Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics.

Kostara C Diagnostics (Basel). 2023; 13(4).

PMID: 36832218 PMC: 9954993. DOI: 10.3390/diagnostics13040721.

References

Bajnok L, Csongradi E, Seres I, Varga Z, Jeges S, Peti A . Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis. 2007; 197(1):363-7. DOI: 10.1016/j.atherosclerosis.2007.06.001. View

Li W, Costa L, Furlong C . Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health. 1993; 40(2-3):337-46. DOI: 10.1080/15287399309531798. View

Mutlu-Turkoglu U, Oztezcan S, Telci A, Orhan Y, Aykac-Toker G, Sivas A . An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med. 2003; 2(4):171-4. DOI: 10.1007/s102380300002. View

Tabur S, Torun A, Sabuncu T, Turan M, Celik H, Ocak A . Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur J Endocrinol. 2009; 162(3):535-41. DOI: 10.1530/EJE-09-0732. View

Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F . Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2004; 90(3):1728-33. DOI: 10.1210/jc.2004-0486. View

Beer S, Moren X, Ruiz J, James R . Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects. Nutr Metab Cardiovasc Dis. 2006; 16(7):457-65. DOI: 10.1016/j.numecd.2005.09.005. View

Kontush A, Chantepie S, Chapman M . Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003; 23(10):1881-8. DOI: 10.1161/01.ATV.0000091338.93223.E8. View

Ferretti G, Bacchetti T, Busni D, Rabini R, Curatola G . Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab. 2004; 89(6):2957-62. DOI: 10.1210/jc.2003-031897. View

McElveen J, Mackness M, Colley C, Peard T, Warner S, Walker C . Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986; 32(4):671-3. View

10.

Mirdamadi H, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G . The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol. 2008; 66(3):366-74. PMC: 2526235. DOI: 10.1111/j.1365-2125.2008.03213.x. View

11.

Sorenson R, Teiber J, La Du B . The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996; 33(3):498-507. DOI: 10.1006/geno.1996.0225. View

12.

Altuner D, Suzen S, Ates I, Koc G, Aral Y, Karakaya A . Are PON1 Q/R 192 and M/L 55 polymorphisms risk factors for diabetes complications in Turkish population?. Clin Biochem. 2011; 44(5-6):372-6. DOI: 10.1016/j.clinbiochem.2010.12.019. View

13.

Mackness B, Durrington P, Abuashia B, Boulton A, Mackness M . Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond). 2000; 98(3):355-63. View

14.

HUMBERT R, Adler D, Disteche C, Hassett C, Omiecinski C, Furlong C . The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3(1):73-6. DOI: 10.1038/ng0193-73. View

15.

Macan M, Vrkic N, Lucic Vrdoljak A, Radic B, Bradamante V . Effects of high sucrose diet, gemfibrozil, and their combination on plasma paraoxonase 1 activity and lipid levels in rats. Acta Biochim Pol. 2010; 57(3):321-6. View

16.

Sorenson R, Bisgaier C, Aviram M, Hsu C, Billecke S, La Du B . Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999; 19(9):2214-25. DOI: 10.1161/01.atv.19.9.2214. View

17.

Vanizor Kural B, Orem C, Uydu H, Alver A, Orem A . The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis. 2004; 15(5):277-83. DOI: 10.1097/01.mca.0000135221.32523.a1. View

18.

Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A . The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol. 2002; 53(3):463-75. View

19.

Yamada A, Shoji T, Tahara H, Emoto M, Nishizawa Y . Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism. 2001; 50(7):805-11. DOI: 10.1053/meta.2001.24215. View

20.

Ergun M, Yurtcu E, Demirci H, Ilhan M, Barkar V, Yetkin I . PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem Genet. 2010; 49(1-2):1-8. DOI: 10.1007/s10528-010-9376-6. View